Revenue Breakdown
Composition ()
No data
Revenue Streams
Cyclerion Therapeutics Inc (CYCN) generates its revenue primarily from Human Therapeutics, which accounts for 100.0% of total sales, equivalent to $133.00K. Understanding this concentration is critical for investors evaluating how CYCN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Cyclerion Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -114.97%, while the net margin is -111.54%. These profitability ratios, combined with a Return on Equity (ROE) of -24.80%, provide a clear picture of how effectively CYCN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CYCN competes directly with industry leaders such as SNOA and RDHL. With a market capitalization of $5.10M, it holds a leading position in the sector. When comparing efficiency, CYCN's gross margin of 100.00% stands against SNOA's 37.94% and RDHL's 60.60%. Such benchmarking helps identify whether Cyclerion Therapeutics Inc is trading at a premium or discount relative to its financial performance.
